Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/is-hyperkalaemia-in-heart-failure-a-risk-factor-or-a-risk-marker-cIgh1pm0lZ
References (16)
-
B. Pitt, G. Bakris, D. Bushinsky, D. Garza, M. Mayo, Y. Stasiv, H. Christ-schmidt, L. Berman, M. Weir (2015)
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitorsEuropean Journal of Heart Failure, 17
-
T. Thorvaldsen, L. Benson, U. Dahlström, M. Edner, L. Lund (2016)
Use of evidence‐based therapy and survival in heart failure in Sweden 2003–2012European Journal of Heart Failure, 18
-
A. Maggioni, S. Anker, U. Dahlström, G. Filippatos, P. Ponikowski, F. Zannad, O. Amir, O. Chioncel, M. Leiro, J. Drożdż, A. Erglis, E. Fazlibegović, C. Fonseca, F. Fruhwald, P. Gatzov, E. Goncalvesova, M. Hassanein, J. Hradec, A. Kavoliūnienė, M. Lainščak, D. Logeart, B. Merkely, M. Metra, H. Persson, P. Seferovic, A. Temizhan, D. Tousoulis, L. Tavazzi (2013)
Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long‐Term RegistryEuropean Journal of Heart Failure, 15
-
M. Epstein, N. Reaven, S. Funk, K. McGaughey, N. Oestreicher, J. Knispel (2015)
Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors.The American journal of managed care, 21 11 Suppl
-
L. Cooper, L. Benson, R. Mentz, G. Savarese, A. DeVore, J. Carrero, U. Dahlström, S. Anker, M. Lainščak, Adrian Hernandez, B. Pitt, L. Lund (2017)
ASSOCIATION BETWEEN SERUM POTASSIUM LEVEL AND OUTCOMES IN HEART FAILURE WITH REDUCED EJECTION FRACTION: A COHORT STUDY FROM THE SWEDISH HEART FAILURE REGISTRYJournal of the American College of Cardiology, 69
-
S. Anker, M. Kosiborod, F. Zannad, I. Piña, P. McCullough, G. Filippatos, P. Meer, P. Ponikowski, H. Rasmussen, P. Lavin, Bhupinder Singh, A. Yang, P. Deedwania (2015)
Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS‐9) in heart failure patients: results from a phase 3 randomized, double‐blind, placebo‐controlled trialEuropean Journal of Heart Failure, 17
-
Ponikowski (2016)
Developed with the special contribution of the Heart Failure Association (HFA) of the ESCEur J Heart Fail, 18
-
Mette Aldahl, A. Jensen, Line Davidsen, Matilde Eriksen, Steen Hansen, B. Nielsen, M. Krogager, L. Køber, C. Torp-Pedersen, P. Søgaard (2017)
Associations of serum potassium levels with mortality in chronic heart failure patientsEuropean Heart Journal, 38
-
P. Ponikowski, A. Voors, S. Anker, H. Bueno, J. Cleland, Andrew Coats, V. Falk, J. González-Juanatey, V. Harjola, E. Jankowska, M. Jessup, C. Linde, P. Nihoyannopoulos, John Parissis, B. Pieske, Jillian Riley, Giuseppe Rosano, L. Ruilope, F. Ruschitzka, Frans Rutten, P. Meer (2016)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Journal of Heart Failure, 18
-
Jiacong Luo, S. Brunelli, Donna Jensen, A. Yang (2016)
Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function.Clinical journal of the American Society of Nephrology : CJASN, 11 1
-
O. Vardeny, B. Claggett, I. Anand, P. Rossignol, Akshay Desai, F. Zannad, B. Pitt, S. Solomon (2014)
Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor AntagonistCirculation: Heart Failure, 7
-
M. Edner, L. Benson, U. Dahlström, L. Lund (2015)
Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study.European heart journal, 36 34
-
J. Ferreira, P. Rossignol, J. Machu, Abhinav Sharma, N. Girerd, S. Anker, J. Cleland, K. Dickstein, G. Filippatos, H. Hillege, C. Lang, J. Maaten, M. Metra, L. Ng, P. Ponikowski, N. Samani, D. Veldhuisen, A. Zwinderman, A. Voors, F. Zannad (2017)
Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT‐CHFEuropean Journal of Heart Failure, 19
-
L. Lund, J. Carrero, B. Farahmand, K. Henriksson, Åsa Jonsson, T. Jernberg, U. Dahlström (2017)
Association between enrolment in a heart failure quality registry and subsequent mortality—a nationwide cohort studyEuropean Journal of Heart Failure, 19
-
Rossignol (2014)
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)Circ Heart Fail, 7
-
Joost Beusekamp, J. Tromp, H. Wal, S. Anker, J. Cleland, K. Dickstein, G. Filippatos, P. Harst, H. Hillege, C. Lang, M. Metra, L. Ng, P. Ponikowski, N. Samani, D. Veldhuisen, A. Zwinderman, P. Rossignol, F. Zannad, A. Voors, P. Meer (2018)
Potassium and the use of renin–angiotensin–aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT‐CHFEuropean Journal of Heart Failure, 20
- Publisher
- Wiley
- Copyright
- © 2018 The Authors. European Journal of Heart Failure © 2018 European Society of Cardiology
- ISSN
- 1388-9842
- eISSN
- 1879-0844
- DOI
- 10.1002/ejhf.1175
- pmid
- 29493052
- Publisher site
- See Article on Publisher Site
Abstract
Journal
European Journal of Heart Failure – Wiley
Published: Jan 1, 2018